FeesSafety
Pluang+

Qualstar files Form 10 with SEC, advancing plans to list on a National Securities Exchange.

Company Fundamentals
04 Nov 2026, 18:02 WIB
GlobeNewsWire
View Source
Bullish
Qualstar files Form 10 with SEC, advancing plans to list on a National Securities Exchange.

Qualstar Corp. has filed a Registration Statement on Form 10 with the U.S. SEC as part of its plan to uplist to a National Securities Exchange. This filing marks a key step in enhancing corporate governance and financial transparency, enabling Qualstar to provide comprehensive audited financial reports. The registration, effective January 3, 2027, will require the company to resume regular SEC reporting. Qualstar aims to strengthen its market position and pursue growth through this move.

Qualstar Corp.'s recent SEC filing provides context for readers interested in related market activity. For readers following Technology-sector US stocks on Pluang, here is the market snapshot as of Nov 04, 2026 22:42 WIB: out of 150 priced stocks, 88 rose and 62 fell. Notable movers include Core Scientific Inc (CORZ) at USD 12.84 with a 1-day change of -9.87% and 100% buy order activity, Applovin Corporation (APP) at USD 269.71 up 9.86% with 100% buy orders, and Iris Energy Limited (IREN) at USD 22.19 down 9.28% with 95% sell orders and a typical hold time of 31 days on Pluang.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
32 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
32 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
32 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
32 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
32 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App